INTRODUCTION
The inflammatory response can be suppressed by a variety of methods, each of which blocks one or more steps in a sequence leading to increased vasopermeability and the accumulation of leukocytes. Examples of anti-inflammatory agents include corticosteroids which, amont other things, suppress chemotactic responses of leukocytes (1) , complement-blocking agents that inactivate substrates involved in the generation of inflammatory mediators (2) , neutrophil-depleting agents (3) , and nonsteroidal drugs (like aspirin) that block prostaglandin synthesis (4) .
Present in normal human serum is a chemotactic factor inactivator (CFI)' that irreversibly inhibits leukotactic factors, presumably by its aminopeptidase activity (5, 6) . In humans with increased levels of CFI in the serum, an association has been found with defective expression of inflammatory reactions as maniReceived for publication 15 October 1976 and in revised form 20 January 1977. 1 Abbreviations used in this paper: BSA, bovine serum albumin; CFI, chemotactic factor inactivator.
fested by skin tests (7) (8) (9) (10) . These observations have suggested that CFI is an important regulator of the inflammatory response. In this communication direct evidence is presented to show that purified human CFI is able to block acute inflammatory reactions induced in rat dermis and lung by immune complexes.
METHODS
Immunologic vasculitis. Reversed passive Arthus reactions were induced in 250-g male Sprague-Dawley rats by the intradermal injection of 100 ,ug antibody nitrogen to bovine serum albumin (BSA). This antibody preparation was obtained by isolation of the IgG fraction from immune rabbit serum. Antibody titers were determined by quantitative precipitin reactions. BSA was injected intravenously in the amount of 10 mg (in 0.5 ml). Details of the techniques are given elsewhere (2) . In some experiments, the permeability changes were determined by the intravenous injection of 20 ,tg homologous rat IgG isolated from normal rat serum and labeled with 125I (11) . A given sample of 1251_ IgG containing 105 cpm was injected intravenously together with the BSA into each animal. Appearance of the labeled IgG in skin sites served as a marker of permeability. The degree of permeability in 2-h Arthus reactions was expressed as the amount of radioactivity (determined by gamma ray emission in a crystal scintillation counter) in a 25-mm skin site. These procedures have been described in detail in a recent publication (11) . Vascular damage in the 4-h reaction sites was determined by measurements of diameters of hemorrhage. All biopsy sites were quick-frozen for immunofluorescent assessment of reactant proteins (BSA and rat C3), while portions of all reaction sites were fixed in formaldehyde and processed for routine light microscopy (2).
Formalin-fixed tissue sections stained with hematoxylin and eosin were assessed by light microscopy for intensity of the infiltration by neutrophils. The following grading system was used: +, margination and early diapedesis of neutrophils: 1+, early perivascular infiltration; 2+, interstitial infiltration and pericapillary infiltration in muscularis layer; 3+, diffuse interstistial infiltration; 4+, heavy infiltrates in all cell layers of skin (subepithelial, dermal, subdermal, muscular, and subcutaneous zones). These criteria were established in earlier studies (2) .
The grading of the inflammatory changes in the lung were: , minimal presence of neutrophils in interstitial areas;
1+, presence of large numbers of neutrophils in the intersti- Acute immune complex-induced alveolitis. The specifics of this reaction are fully described elsewhere (11) . The same reagents were used as employed for the reversed passive Arthus reactions. After intratracheal cannulation, 100 ,ug N anti-BSA was instilled intrabronchially, after which BSA (10 mg) with small amounts (see above) of 125I-labeled rat IgG was injected intravenously. Reactions were allowed to progress over a 2-h period, after which time 1.0 ml blood was obtained and the amount of radioactivity determined. After lavage of the pulmonary circulation with 5 ml saline injected into the right ventricle of the heart, lungs were obtained and assessed for radioactivity. One-half of each of the antibody preparation. The non-CFI-treated dermal sites and lungs received 100 ul antibody mixed with 100 ,ul phosphate-buffered (pH 7.4) saline. In some experiments CFI was preheated at 56°C for 2 h before use, to destroy its activity. Various controls and replicate sites were prepared, as described in the appropriate tables. Chemotaxis assay. In vitro leukotactic assays were performed with rabbit neutrophils obtained from glycogeninduced peritoneal exudates. Details of the assay are given elsewhere (5). Rat serum was chemotactically activated by incubation with zymosan, 10 mg/ml serum, at 37°C for Y2 h (13) . Zymosan particles were then removed by centrifugation and chemotactically activated serum tested by itself or after incubation with purified human CFI.
RESULTS
Suppression in vitro of leukotactic factors by CFI. Two experiments, described in Table I , were performed to determine the ability of purified human CFI to inhibit the chemotactic activity generated by incubation of rat serum with zymosan. The chemotactic activity was inhibited by CFI in a dose-dependent manner. In experiment A it was also shown that CFI heated at 56°C for 2 h was, as expected, no longer able to inhibit the chemotactic activity in rat serum. These experiments indicate that human CFI can inhibit the chemotactic activity generated in rat serum by activation of complement. It has previously been shown that the chemotactic activity is associated with products of C5 (13) .
Suppression of inflammation in dermal Arthus reaction. To assess the effect of CFI on the dermal Arthus reaction, it was first necessary to determine the degree of reproducibility of vasopermeability changes (Table III) . In all of the positive control sites, the intensity of the neutrophil infiltration was 2+ (involving walls of vessels and interstitial areas) (Fig.  1) . At sites where CFI had been injected, there was minimal evidence of neutrophil infiltration (+, with cells limited to walls of venules) (Fig. 2) . The permeability changes (due to leakage of 125I-labeled rat IgG) ranged from 1,314 to 2,262 cpm per site, whereas in the presence of CFI, the permeability changes diminished to an extent of 35-56%. If the CFI had been previously heat inactivated, virtually all of the suppression of leukocytic infiltration and permeability changes disappeared (Table III, (13, 15, 16 ). An additional factor apparently involved in the pathogenesis of the reaction may be the C5-cleaving enzyme derived from lysosomal granules of neutrophils (15, 16 (2, 3, 11) . Complement reduction so as to block development of the reactions requires complete inactivation of the total hemolytic activity of serum and reduction of C3 to <5% of its normal level (11, 13, 15) . Corticosteroid treatment of guinea pigs sufficient to inhibit development of the Arthus reaction requires >50 mg for each animal (1) . Our studies do not provide any evidence that CFI interferes with the development of immunologically induced inflammatory reactions by an effect on intact complement components. Neither is there any evidence that the formation in vitro of complementfixing immune complexes is interferred with by the presence of CFI. There is a possibility that CFI, aside from its ability to destroy complement-derived leukotactic factors, might be able to alter permeability factors. If it unexpectedly has an ability to impair the effects of vasoactive amines, this is probably a moot point, since all studies to date have provided Suppression of Inflammationnegative evidence for the role of vasoactive amines in the Arthus reaction (reviewed in reference 17). Although it has been demonstrated that bradykinin can be inactivated by CFI (6) , no statements can be made regarding the role of this kinin in immune complex-induced inflammatory reactions, since no direct and highly specific method for blocking the generation of, or the action of, bradykinin in vivo has yet been devised.
The demonstration that CFI can block immune complex-induced and complement-mediated inflammatory reactions in rats provides added support for the role of CFI as an important regulator of the inflammatory system. It has been recently demonstrated that elevated CFI levels occur in Hodgkin's disease (6), hepatic cirrhosis (8), sarcoidosis (9) , and in lepromatous leprosy (7) . In the last instance, a good correlation exists between elevated levels of the inhibitor and the inability of the patients to express cellular inflammatory reactions in the skin. Similar correlations between defective inflammatory responses in humans and the presence of a serum associated chemotactic inhibitor with CFI-like properties have been reported by others (18) .
To what extent CFI will be useful in blocking other inflammatory reactions is as yet not known. On the other hand, the results reported in this paper give considerable promise that CFI, a naturally occurring inhibitor of the leukotactic system, may represent a new and highly specific approach to anti-inflammatory therapy.
